

---

# Multiscale guidance of protein structure prediction with heterogeneous cryo-EM data

---

**Rishwanth Raghu**  
Princeton University  
rraghu@princeton.edu

**Axel Levy**  
Stanford University  
axlevy@stanford.edu

**Gordon Wetzstein**  
Stanford University  
gordon.wetzstein@stanford.edu

**Ellen D. Zhong**  
Princeton University  
zhonge@princeton.edu

## Abstract

Protein structure prediction models are now capable of generating accurate 3D structural hypotheses from sequence alone. However, they routinely fail to capture the conformational diversity of dynamic biomolecular complexes, often requiring heuristic MSA subsampling approaches for generating alternative states. In parallel, cryo-electron microscopy (cryo-EM) has emerged as a powerful tool for imaging near-native structural heterogeneity, but is challenged by arduous pipelines to transform raw experimental data into atomic models. Here, we bridge the gap between these modalities, combining cryo-EM density maps with the rich sequence and biophysical priors learned by protein structure prediction models. Our method, CryoBoltz, guides the sampling trajectory of a pretrained biomolecular structure prediction model using both global and local structural constraints derived from density maps, driving predictions towards conformational states consistent with the experimental data. We demonstrate that this flexible yet powerful inference-time approach allows us to build atomic models into heterogeneous cryo-EM maps across a variety of dynamic biomolecular systems including transporters and antibodies.

## 1 Introduction

Proteins and other macromolecules in our cells are constantly vibrating, deforming, and interacting with other surrounding molecules. Characterizing the variability of their atomic structures, i.e., of the relative 3-dimensional (3D) locations of their atoms, can deepen our understanding of the complex chemical mechanisms underlying basic biological systems. For example, understanding how a driver mutation can alter the probability of certain conformational states has applications ranging from drug design [25] to molecular engineering [21].

A variety of experimental methods for protein structure determination have been developed, with X-ray crystallography and cryo-electron microscopy (cryo-EM) being the most widely used today. In cryo-EM, a series of breakthroughs in both hardware [80, 9, 24, 29] and software [69, 27, 68, 64] led to the so-called “resolution revolution” [47], resulting in routine near-atomic resolution structure determination for well-behaved purified protein samples. Cryo-EM, in particular, also possesses the ability to measure and reconstruct the conformational landscape of dynamic biomolecular complexes [68, 64, 94, 10, 62, 63]. However, these experiments are still complex, costly, and time consuming, requiring expensive microscopes and facilities, as well as hours to days of data processing through iterative computational pipelines [49]. Notably, current reconstruction algorithms only output 3D “density maps” that approximate the electron scattering potential of the molecule.




Figure 1: **Problem statement.** Diffusion-based structure prediction models [1, 88] can sample different conformations, but the generated ensemble is generally peaked around a single conformation. A cryo-EM experiment probes the full conformational landscape but current reconstruction algorithms only provide density maps, not atomic models. With CryoBoltz, we guide the diffusion process in atomic space with experimental cryo-EM measurements to increase sample diversity and more faithfully reflect the true conformational ensemble.

Fitting atomic models within these maps is a significant computational challenge for which existing methods [85, 51, 82, 81, 35, 39] only provide partial solutions that need to be manually refined.

Building on decades of data acquisition, processing, and curation [7, 8], machine-learning-based sequence-to-structure models were developed and trained on publicly available structural data [41, 3, 52, 1]. These models, however, are still trained to map a given sequence to a unique, most likely structure and are therefore bound to viewing proteins as static objects. Shifting structure prediction models to a dynamic paradigm constitutes one of today's main challenges for structural biology.

Recent exploratory lines of work have attempted to address this outstanding challenge. MSA subsampling methods, for example, rely on randomly masking input sequence data to broaden the diversity of output structures [87, 23, 43, 36]. Despite results showing improved diversity on specific systems, MSA subsampling methods remain an active area of research, with no clear consensus yet regarding their performance. Moreover, these methods are not well suited for complexes that can adopt many different conformational states or a continuum of conformational states. Other works, including AlphaFlow [40] and BioEmu [50], investigated incorporating physics-based molecular dynamics simulation as additional training data. These works also showed greater variability among output structures but were mainly demonstrated on small peptides, additionally requiring costly training and relying on simulations that may not capture realistic atomic motions.

Here we introduce a method, CryoBoltz, that leverages heterogeneous cryo-EM data to guide the sampling process of a diffusion-based structure prediction algorithm (Figure 1). Our implementation is based on Boltz-1 [88], an open-source sequence-conditioned diffusion model heavily inspired by the state-of-the-art model AlphaFold3 [1]. Through a multiscale guidance mechanism, CryoBoltz combines the structural information learned by the pretrained diffusion model with experimentally-captured data, producing structures consistent with the cryo-EM data. Importantly, our method does not require an additional training step, while effectively mitigating the single-structure bias of current structure prediction models. We demonstrate results on both synthetic and real cryo-EM maps of dynamic biomolecular complexes.

## 2 Background

### 2.1 Diffusion-Based Sampling in AlphaFold3

Recent advances in protein structure prediction from sequences are exemplified by major breakthroughs such as AlphaFold2 [41] and AlphaFold3 [1]. While AlphaFold2 predicts static structures with remarkable accuracy, AlphaFold3 introduces a diffusion modeling head within its structure module, enabling generative sampling of different conformations, conditioned on the same sequence.

Specifically, AlphaFold3 utilizes a diffusion model operating directly in the space of atomic coordinates,  $\mathbf{x} \in \mathbb{R}^{N \times 3}$  where  $N$  represents the number of modeled atoms. Given a sequence  $\mathbf{s}$ , we call  $p_0(\mathbf{x}|\mathbf{s})$  the distribution of conformations of the folded protein (or complex) at ambient temperature. We then call  $p_t(\mathbf{x}|\mathbf{s})$  the marginal distribution of conformations obtained by sampling  $\mathbf{x}_0$  from  $p_0(\mathbf{x}|\mathbf{s})$  and simulating the *forward* diffusion process

$$d\mathbf{x} = \mathbf{f}(\mathbf{x}, t)dt + g(t)d\mathbf{w}, \quad (1)$$

from 0 to  $t$ , where  $\mathbf{f}(\mathbf{x}, t)$  and  $g(t)$  are predefined drift and diffusion functions while  $d\mathbf{w}$  represents a standard Wiener process in atomic coordinate space. The drift and diffusion functions are chosen such that  $p_T(\mathbf{x}|\mathbf{s}) \approx \mathcal{N}(\mathbf{0}, \mathbf{I})$  for some  $T \in \mathbb{R}$ . One way to sample from the target distribution  $p_0(\mathbf{x}|\mathbf{s})$  is then to sample  $\mathbf{x}_T$  from  $\mathcal{N}(\mathbf{0}, \mathbf{I})$  and simulate the *reverse* diffusion process

$$d\mathbf{x} = (\mathbf{f}(\mathbf{x}, t) - g(t)^2 \nabla_{\mathbf{x}} \log p_t(\mathbf{x}|\mathbf{s})) dt + g(t)d\mathbf{w} \quad (2)$$

from  $T$  to 0 [2, 34]. In the above equation, the score function  $\nabla_{\mathbf{x}} \log p_t(\mathbf{x}|\mathbf{s})$  is unknown and implicitly depends on the target distribution. AlphaFold3 therefore uses an approximation of the score function, called  $s_\theta(\mathbf{x}, \mathbf{s}, t)$ . This “score model” can be obtained using a finite set of samples from  $p_0(\mathbf{x}|\mathbf{s})$  and a training strategy based on denoising score matching [84, 76].

Boltz-1 closely follows the architecture and framework of AlphaFold3 with minor modifications, achieving comparable accuracy in predicting biomolecular complex structures [88].

## 2.2 Likelihood-Based Guidance

In an “inverse problem”, one aims at recovering an unknown object  $\mathbf{x}$  from a measurement  $\mathbf{y}$ , given a known “likelihood model”  $p(\mathbf{y}|\mathbf{x})$ . Inverse problems are often framed as posterior sampling problems, i.e., they aim at sampling from the posterior  $p(\mathbf{x}|\mathbf{y})$ . Using Bayes’ rule, the posterior can be decomposed as a product of the likelihood,  $p(\mathbf{y}|\mathbf{x})$ , and the prior distribution over  $\mathbf{x}$ .

In this context, several works have recently shown that pretrained diffusion models can be interpreted as implicitly defined priors and therefore used to solve posterior sampling problems [38, 75, 11, 12, 74, 45, 46, 86], as surveyed in [20]. Effectively, these methods are able to “guide” a diffusion model using a measurement  $\mathbf{y}$  and its corresponding likelihood model. The key insight of these works lies in noticing that the score function of the posterior can be re-written as a sum:  $\nabla_{\mathbf{x}} \log p_t(\mathbf{x}|\mathbf{y}) = \nabla_{\mathbf{x}} \log p_t(\mathbf{x}) + \nabla_{\mathbf{x}} \log p(\mathbf{y}|\mathbf{x}_t = \mathbf{x})$ . The first term is directly approximated by the pretrained score model  $s_\theta(\mathbf{x}, \mathbf{s}, t)$ , but the challenge lies in the second term. The conditional probability  $p(\mathbf{y}|\mathbf{x}_t)$  can be written as a conditional expectation  $\mathbb{E}_{\mathbf{x}_0 \sim p(\mathbf{x}_0|\mathbf{x}_t)}[p(\mathbf{y}|\mathbf{x}_0)]$ , but approximating this expectation with Monte Carlo samples is not a computationally tractable option, because sampling  $n$  times from the conditional distribution  $p(\mathbf{x}_0|\mathbf{x}_t)$  requires solving  $n$  differential equations. In ScoreALD, Jalal et al. [38] first suggested to replace the latter distribution with a Dirac delta centered on  $\mathbf{x}$ , effectively replacing  $p(\mathbf{y}|\mathbf{x}_t)$  with  $p(\mathbf{y}|\mathbf{x})$ . Despite promising results on low-noise and linear inverse problems, ScoreALD tends to drive samples off the diffusion manifold, i.e., in regions where  $p_t(\mathbf{x}) \ll 1$ , where the score model was only sparsely supervised and is therefore highly inaccurate. To mitigate this issue, Chung et al. [12] suggested in the DPS algorithm to center the Dirac delta distribution on  $\hat{\mathbf{x}}_\theta(\mathbf{x}, t) = \mathbb{E}_{\mathbf{x}_0 \sim p(\mathbf{x}_0|\mathbf{x}_t = \mathbf{x})}[\mathbf{x}_0]$ , which can be expressed as an affine function of  $s_\theta(\mathbf{x}, t)$  with Tweedie’s formula [77, 66, 26]. The *guided* reverse diffusion process is therefore defined as

$$d\mathbf{x} = \left( \mathbf{f}(\mathbf{x}, t) - g(t)^2 s_\theta(\mathbf{x}, t) - \lambda(t) \underbrace{\nabla_{\mathbf{x}} \log p(\mathbf{y}|\mathbf{x}_0 = \hat{\mathbf{x}}_\theta(\mathbf{x}, t))}_{\tilde{s}_\theta(\mathbf{y}, \mathbf{x}, t)} \right) dt + g(t)d\mathbf{w}, \quad (3)$$

where  $\tilde{s}_\theta(\mathbf{y}, \mathbf{x}, t)$  is an additional guidance term.

In parallel to the guidance-based approach, other works have attempted to frame the posterior sampling problem as a problem of variational inference [30, 55], but remain limited by the expressivity of the variational family (e.g., Gaussian distributions [55]) or by the necessity to repeatedly solve initial-value problems [30]. Most recently, MCMC-based strategies like DAPS [91] proposed to correct previous sampling methods with an equilibration step based on MCMC sampling (e.g., Langevin dynamics or Hamiltonian Monte Carlo) and showed improved performance on high-noise or highly nonlinear problems. However, owing to the simplicity and effectiveness of the DPS algorithm for our problem of interest, we base our guiding mechanism on the DPS framework.




Figure 2: **Overview of the guidance mechanism.** The diffusion process starts with a “warm up” stage where the score model is only conditioned on the sequence. During “global guidance”, the structure is guided to minimize its distance to a point cloud representation of the input cryo-EM map. During “local guidance”, it is guided to maximize its consistency with the original input map. Finally, the last “relaxation” steps are unguided and allow the model to correct fine-grained details.

### 2.3 Forward Model for Cryo-EM Maps

Cryo-EM reconstructs a 3D electron scattering potential from many independent 2D projection images of frozen biomolecular complexes. The reconstructed density map  $\mathbf{y}$  is usually represented as a 3D array:  $\mathbf{y} \in \mathbb{R}^{w \times h \times d}$ . In the forward model, a given structure’s cryo-EM density is typically modeled as a sum of Gaussian form factors centered on each atom. Formally, the observed density map can be modeled as  $\mathbf{y} = \mathcal{B}(\Gamma(\mathbf{x}, \mathbf{s})) + \eta$  [22], where  $\Gamma$  is an operator that sums isotropic Gaussians centered on each heavy (non-hydrogen) atom in  $\mathbf{x}$ . Their amplitudes and variances are tabulated [33] and typically depend on the chemical elements in  $\mathbf{x}$ .  $\mathcal{B}$  represents the effect of “B-factors” [44] and can be viewed as a spatially dependent blurring kernel modeling molecular motions and/or signal damping by the transfer function of the electron microscope. Finally,  $\eta$  models i.i.d. Gaussian noise.

## 3 Methods

In this section, we describe how CryoBoltz uses an input cryo-EM map to guide a diffusion process in atomic space. Our implementation is based on the DPS algorithm (Section 2.2) [12].

### 3.1 Overview: Multiscale Guidance

Because the forward model turning atomic models  $\mathbf{x}$  into density maps is highly nonlinear (Section 2.3), the likelihood function  $p(\mathbf{y}|\mathbf{x})$  is multimodal w.r.t.  $\mathbf{x}$ , making the posterior  $p(\mathbf{x}|\mathbf{y}) \propto p(\mathbf{y}|\mathbf{x})p(\mathbf{x})$  rugged and hard to sample from with score-based methods. In order to regularize the target ensemble distribution in the early diffusion steps, CryoBoltz uses a global-to-local guidance strategy that ignores high-resolution information until the later diffusion steps.

First, we use  $T_w$  steps of unguided reverse diffusion, only conditioning the score model on the sequence  $\mathbf{s}$ , to bootstrap (i.e., “warm up”) the atomic model and obtain a structure close to the one the diffusion model is initially biased towards (Figure 1, left), following Equation 2. We then use



$T_g$  steps of a “global guidance” strategy, further described in Section 3.2, followed by  $T_l$  steps of a “local guidance” stage, described in Section 3.3. Finally, the last  $T_r$  diffusion steps are unguided to help solve high-resolution inconsistencies (e.g., steric clashes). Figure 2 provides an overview of our multiscale guidance strategy.

### 3.2 Global Guidance

At the beginning of the global guidance stage, the density map  $\mathbf{y} \in \mathbb{R}^{w \times h \times d}$  is transformed into a 3D point cloud  $\mathbf{Y} \in \mathbb{R}^{k \times 3}$ . This conversion is done using the weighted  $k$ -means clustering algorithm with a predefined number of clusters  $k$  dependent on the number of atoms in the system and the voxel size of the map (see details in the Appendix). This point cloud, inspired by the volumetric shape constraints in Chroma [37], provides a compact and low-resolution representation of the map that can be used to efficiently guide the diffusion process towards the global shape of the protein complex. A key benefit of the point cloud representation is that the distance between  $\mathbf{x}$  and  $\mathbf{Y}$  can be defined using standard distances derived from optimal-transport theory, like the Sinkhorn divergence  $\mathcal{D}(\mathbf{x}, \mathbf{Y})$ , a regularized version of the Wasserstein distance [60]. In the first global guidance step, the intermediate sample  $\mathbf{x}$  is aligned with the density map prior to computing the Sinkhorn divergence (see Appendix for more details).

Following the DPS framework, we define the guided diffusion process using Equation 3 (with sequence-conditioning in the pretrained score model), where the guidance term is defined as

$$\tilde{s}_\theta(\mathbf{y}, \mathbf{x}, \mathbf{s}, t) = -\nabla_{\mathbf{x}} \mathcal{D}(\hat{\mathbf{x}}_\theta(\mathbf{x}, \mathbf{s}, t), \mathbf{Y}). \quad (4)$$

The schedule of the guidance strength  $\lambda(t)$  is described in the Appendix. Note here that the global guidance term is not directly derived from a physics-based likelihood model, but rather defined heuristically in order for the atomic model  $\mathbf{x}$  to fit the low-resolution details of the cryo-EM map.

### 3.3 Local Guidance

During local guidance, the original density map is used and the guidance term of Equation 3 is directly derived from the forward model described in Section 2.3, i.e.,

$$\tilde{s}_\theta(\mathbf{y}, \mathbf{x}, \mathbf{s}, t) = -\nabla_{\mathbf{x}} \|\mathbf{y} - \mathcal{B}(\Gamma(\hat{\mathbf{x}}_\theta(\mathbf{x}, \mathbf{s}, t), \mathbf{s}))\|^2. \quad (5)$$

At this stage, the guidance term includes all the structural information captured in the density map, including higher resolution details, and derives directly from physics-based assumptions on the cryo-EM forward model and noise model.

### 3.4 Related Work

Our work proposes to guide a pretrained diffusion model operating on atomic coordinates using experimental cryo-EM data. Equivalently, our method can be seen as a model building method leveraging a pretrained diffusion model as a regularizer.

First developed for X-ray crystallography [13], model building methods were later adapted to operate on cryo-EM data [85, 51, 82, 81] but the obtained atomic models were often incomplete and needed refinement [73]. Machine-learning-based methods were also developed, either relying on U-Net architectures [72, 92, 61] or combining 3D transformers with Hidden Markov Models [32]. He et al. [35] first made use of sequence information in EMBuild, and ModelAngelo [39] has recently established a new state of the art for automated *de novo* model building. Combining a GNN-based architecture with preprocessed sequence information [65], ModelAngelo outperforms previous approaches. However, its performance relies on high-resolution maps (below 4 Å) and often yields incomplete models on blurry, low-resolution data (Figure 5, for example). As a result, manual model building remains the prevailing solution in these challenging regimes, particularly in those involving flexible or heterogeneous complexes.

The possibility of using structure prediction models as regularizers for 3D reconstruction problems was only demonstrated very recently. In ROCKET, Fadini et al. [28] introduced a method to use AlphaFold2 [41] as a prior for building atomic models that are consistent with cryo-EM, cryo-ET or X-ray crystallography data. The method regularizes the problem by transferring the optimization from atomic space to the latent space of AlphaFold2. In contrast, our method leverages AlphaFold3’s

Table 1: **Quantitative evaluation with synthetic maps (STP10 [6] and CH67 antibody [70]) and ablation study.** We report the Root Mean Square Deviation (RMSD) for all atoms, the  $C\alpha$  RMSD, and the template-modeling (TM) score. For CH67, we also report the RMSD for the  $C\alpha$  atoms in the CDR H3 loop (local RMSD). The last two columns show an ablation study on the guidance mechanism. The mean across 3 replicates is reported for the best of 25 samples (lowest all-atom RMSD). Random MSA subsampling of Boltz-1 [88] (Boltz-1 + MSA sub.) is run with MSA depths of 64, 128, 256, 512, and 1024, each producing 5 samples. **Bold** indicates best value. AF3 is AlphaFold3 [1].

| Structure       | Metrics                                        | CryoBoltz    | Boltz-1 | Boltz-1 +<br>MSA sub. | AF3   | Local<br>only | Global<br>only |
|-----------------|------------------------------------------------|--------------|---------|-----------------------|-------|---------------|----------------|
| STP10 (inward)  | RMSD ( $\text{\AA}$ , $\downarrow$ )           | <b>1.057</b> | 3.815   | 3.768                 | 1.263 | 3.860         | 1.287          |
|                 | $C\alpha$ RMSD ( $\text{\AA}$ , $\downarrow$ ) | <b>0.371</b> | 3.554   | 3.513                 | 0.623 | 3.559         | 0.778          |
|                 | TM score ( $\uparrow$ )                        | <b>0.998</b> | 0.863   | 0.865                 | 0.994 | 0.862         | 0.990          |
| STP10 (outward) | RMSD                                           | <b>0.888</b> | 2.656   | 2.542                 | 4.478 | 2.722         | 1.164          |
|                 | $C\alpha$ RMSD                                 | <b>0.440</b> | 2.419   | 2.295                 | 4.228 | 2.458         | 0.779          |
|                 | TM score                                       | <b>0.997</b> | 0.948   | 0.953                 | 0.828 | 0.946         | 0.991          |
| CH67 antibody   | RMSD                                           | <b>1.048</b> | 1.961   | 1.954                 | 1.887 | 1.443         | 1.281          |
|                 | $C\alpha$ RMSD                                 | <b>0.637</b> | 1.469   | 1.522                 | 1.453 | 0.945         | 0.880          |
|                 | Local RMSD                                     | <b>1.269</b> | 3.120   | 3.270                 | 3.191 | 1.718         | 1.899          |
|                 | TM score                                       | <b>0.994</b> | 0.972   | 0.969                 | 0.971 | 0.990         | 0.988          |


diffusion-based structure module for efficient optimization directly in atomic space. Other works investigated the possibility to guide diffusion-based models using experimental data [54, 53] but were only used to process X-ray crystallography data. In this modality, each measurement provides an average of the contribution of each conformation in the crystal, which inherently limits the extent to which structural variability can be analyzed. Finally, ADP-3D [48] demonstrated diffusion-based model refinement using cryo-EM measurements, but the method requires an initial model (provided, for example, by ModelAngelo [39]) and was not compared to existing structure prediction methods.

## 4 Results

### 4.1 Experimental Setup

**Datasets and metrics.** We evaluate our method on six biomolecular systems. For two of them, we guide CryoBoltz with synthetic density maps (STP10 [6] and CH67 antibody [70]) and use real, experimental maps for the other four systems (P-glycoprotein [14], Pma1, CYP102A1, and YbbAP [56]). We chose these four systems because (1) they have two or more density maps corresponding to different conformational states; (2) the corresponding atomic models were deposited after the Boltz-1 [88] training cutoff; (3) they are composed of two or fewer unique chains, so that an accurate unguided Boltz-1 prediction can be obtained; and (4) the sequence is shorter than 2,200 residues, which we found to be the max sequence length that could fit in Boltz-1. For three of these systems (P-glycoprotein, CYP102A1, and YbbAP), at least one map is of lower resolution ( $>4$   $\text{\AA}$ ). To assess the quality of a generated structure, we align it to the deposited (reference) structure pairing  $\alpha$ -carbons, then compute  $C\alpha$  root mean square deviation (RMSD), all-atom RMSD, and template-modeling (TM) score [93]. We sample 25 structures for each of three model replicates. We additionally report map-model fit metrics in Supplementary Table B2.

**Baselines.** We compare CryoBoltz against the diffusion-based structure prediction models Boltz-1 [88] and AlphaFold3 [1]. We additionally evaluate Boltz-1 with MSA subsampling, producing 5 samples each for 64, 128, 256, 512, and 1024 randomly drawn MSA sequences. On the experimental datasets, we also compare our results to those obtained with the model building algorithm ModelAngelo [39].




**Figure 3: Results on STP10 [6].** **a)** CryoBoltz can predict both the outward and inward states, when guided with the respective cryo-EM density map. Best sample (lowest all-atom RMSD across all model replicates) is shown. **b, c)** Current structure prediction models are biased towards one of these states. Boltz-1 [88] only predicts the outward state (**b**) while AlphaFold3 [1] only predicts the inward state (**c**). Five best samples relative to the outward and inward PDB structures, respectively, are shown.

## 4.2 Synthetic datasets

**STP10.** We demonstrate our method on the sugar transporter protein STP10, a plant protein that switches between inward-facing and outward-facing conformations as it shuttles substrates across the cell membrane [6]. From the deposited atomic models of these structures (PDB: 7AAQ, 7AAR) [4, 5], we generate synthetic density maps at a resolution of 2 Å using the *molmap* function in ChimeraX [59]. In Figure 3, we show that density-guided diffusion allows for accurate modeling of both conformational states. While unguided Boltz-1 only samples the outward conformation, CryoBoltz guidance drives the rearrangement of helices to sample the inward conformation. MSA subsampling slightly improves the accuracy of Boltz-1 but still only samples the outward conformation. AlphaFold3, in contrast, only samples the inward conformation. As seen in Table 1, CryoBoltz not only models both conformations, but also improves the accuracy of the predictions over their unguided counterparts, achieving an all-atom RMSD below 1 Å for the outward state.

**CH67 antibody.** CH67 is an antibody whose Fab domain binds the influenza hemagglutinin receptor during the human immune response [70]. Responsible for this interaction is the complementarity-determining region (CDR) H3, a short loop that is highly variable across antibody families and thus is modeled poorly by protein structure prediction methods. To assess the ability of our method to cope with the lower resolutions typically obtained for antibody cryo-EM maps, we simulate a 4 Å density map of the CH67 Fab domain (PDB: 4HKX) [71]. In Figure 4, we show that CryoBoltz accurately models the CDR H3 loop, correctly placing the backbone and most of the side chains. With some samples achieving a local RMSD below 1 Å on this region (Supplementary Figure B2), our method improves over Boltz-1 and AlphaFold3 (Table 1), due to both better global modeling of the full Fab structure as well as local modeling of the H3 loop itself (Supplementary Figure B1).



**Figure 4: Results on CH67 antibody [70].** CryoBoltz fits the CDR H3 loop more accurately than Boltz-1 [88] and AlphaFold3 [1]. Three best samples (lowest all-atom RMSD across all model replicates) are shown on the right.

Table 2: **Quantitative evaluation using real cryo-EM density maps of four biomolecular systems.** We report the mean all-atom RMSD (Å), C $\alpha$  RMSD (Å) and TM score for the best of 25 samples (lowest all-atom RMSD) across 3 model replicates. We indicate the resolution of the input map (res.) as well as the completeness (comp.) of the model built by ModelAngelo (MA) [39] (percentage of modeled over deposited residues). Pgp is P-glycoprotein [14] and CYP is CYP102A1. **Bold** indicates best value.

| Structure        | Res.<br>(Å) | CryoBoltz    |                    |              | Boltz-1     |                    |             | AlphaFold3  |                    |             | ModelAngelo  |             |
|------------------|-------------|--------------|--------------------|--------------|-------------|--------------------|-------------|-------------|--------------------|-------------|--------------|-------------|
|                  |             | RMSD<br>all  | RMSD<br>C $\alpha$ | TM<br>score  | RMSD<br>all | RMSD<br>C $\alpha$ | TM<br>score | RMSD<br>all | RMSD<br>C $\alpha$ | TM<br>score | Comp.<br>(%) | TM<br>score |
| Pgp (apo)        | 4.3         | <b>1.382</b> | <b>1.208</b>       | <b>0.989</b> | 6.994       | 7.194              | 0.767       | 3.827       | 3.865              | 0.904       | 40.3         | 0.361       |
| Pgp (inward)     | 4.4         | <b>1.348</b> | <b>1.187</b>       | <b>0.989</b> | 5.630       | 5.692              | 0.828       | 2.692       | 2.663              | 0.947       | 18.3         | 0.134       |
| Pgp (occluded)   | 4.1         | <b>1.727</b> | <b>1.677</b>       | <b>0.979</b> | 2.929       | 2.904              | 0.942       | 3.440       | 3.420              | 0.921       | 2.3          | 0.010       |
| Pgp (collapsed)  | 4.4         | <b>1.309</b> | <b>1.261</b>       | <b>0.988</b> | 3.425       | 3.412              | 0.917       | 4.568       | 4.554              | 0.864       | 2.5          | 0.010       |
| Pma1 (active)    | 3.25        | <b>2.046</b> | <b>1.776</b>       | <b>0.973</b> | 2.987       | 2.752              | 0.935       | 6.628       | 6.389              | 0.769       | 91.5         | 0.889       |
| Pma1 (inhibited) | 3.52        | <b>1.999</b> | <b>1.590</b>       | <b>0.979</b> | 6.140       | 5.829              | 0.794       | 8.017       | 7.776              | 0.723       | 72.8         | 0.721       |
| CYP (open)       | 6.5         | <b>4.167</b> | <b>3.946</b>       | <b>0.957</b> | 8.532       | 8.439              | 0.788       | 6.490       | 6.361              | 0.890       | 0.0          | 0.000       |
| CYP (closed)     | 4.4         | <b>2.004</b> | <b>1.552</b>       | <b>0.990</b> | 8.784       | 8.667              | 0.743       | 3.585       | 3.391              | 0.946       | 18.9         | 0.102       |
| YbbAP (bound)    | 3.66        | <b>1.320</b> | <b>0.678</b>       | <b>0.997</b> | 3.623       | 3.339              | 0.928       | 3.749       | 3.480              | 0.922       | 81.7         | 0.801       |
| YbbAP (unbound)  | 4.05        | <b>2.454</b> | <b>2.039</b>       | <b>0.974</b> | 7.842       | 7.654              | 0.776       | 4.022       | 3.744              | 0.913       | 55.4         | 0.548       |

### 4.3 Experimental datasets

**P-glycoprotein.** P-glycoprotein is a membrane transporter that conducts cellular export of toxic compounds including chemotherapy drugs, making it an important therapeutic target for inhibition [14]. We test our method on experimental density maps corresponding to four states in the transport cycle: the apo state, inward state, occluded state, and collapsed state (EMD-40226, 40259, 40258, 40227). We mask the maps around their corresponding deposited atomic models (PDB: 8GMG, 8SA1, 8SA0, 8GMJ) [15, 18, 17, 16] in order to remove non-protein detergent density, which is a byproduct of sample preparation for transmembrane proteins. As shown in Figure 5 and Table 2, CryoBoltz samples the full set of conformations, outperforming baselines in all metrics across all four states. We additionally find that ModelAngelo predictions are highly incomplete, with only between 2.3% and 40.3% of residues modeled. We provide ModelAngelo with the original maps as they lead to marginally higher performance.

**Pma1.** We use two experimental maps of a Pma1 monomer (EMD-64135, 64136), corresponding to the active and inhibited states (PDB: 9UGB, 9UGC) [89, 90] of this ATPase. Unguided Boltz only samples the active state, whereas guidance also samples the inhibited state with an all-atom RMSD of 2.00 Å and C $\alpha$  RMSD of 1.59 Å (Table 2, Figure 6). AlphaFold3 predictions are not accurate with respect to either state.

**CYP102A1.** We use two experimental maps of CYP102A1 (EMD-27534, 27536), of resolutions 4.4 Å and 6.5 Å, corresponding to the open and closed states (PDB: 8DME, 8DMG) [78, 79] of this oxygenase. Guidance improves the all-atom RMSD of the closed state from 8.78 Å to 2.00 Å over unguided Boltz-1, whereas for the lower resolution open state map, a more modest improvement from 8.53 Å to 4.17 Å is observed. ModelAngelo only models 18.9% of the 4.4 Å map and none of the 6.5 Å map.

**YbbAP.** We use two experimental maps of the YbbAP transporter [56] (EMD-51292, 51291), corresponding to states in which ATP is bound or unbound (PDB: 9GE7, 9GE6) [58, 57]. Unguided Boltz only samples the bound state, which guidance further improves to an all-atom RMSD of 1.32 Å. The unbound state is additionally obtained through guidance. We observe that MSA subsampling also allows Boltz-1 to sample the unbound sample in some model replicates (Supplementary Table B1).

### 4.4 Ablations

To validate our multiscale approach, we ablate the model by exclusively running the global guidance phase or local guidance phase. As shown in Table 1, while global guidance alone often improves metrics over baselines, local guidance further boosts accuracy by fitting higher-resolution details.




Figure 5: **Results on P-glycoprotein [14].** CryoBoltz recovers distinct states of the protein using four experimental cryo-EM maps. ModelAngelo [39] produces highly incomplete models.

Local guidance alone also improves performance over unguided Boltz-1, but is ultimately insufficient in driving large conformational changes. We report ablations for real density maps in Supplementary Table B1. The combination of local and global guidance leads to better accuracy than either one alone for most of the maps.

## 5 Discussion

This work introduces a guidance mechanism that increases the capability of current diffusion-based structure prediction models. The guiding information, derived from experimental cryo-EM measurements, biases sampling towards atomic models consistent with the observed data. Our method does not require any retraining or finetuning and can be used on top of any available model, thereby making it possible to benefit from their continuous improvement. Through experiments on both synthetic and experimental data, we show that CryoBoltz can increase the diversity of sampled conformations – revealing states that are missed by existing diffusion models – and predict more accurately the structure of regions that are key to function, like CDR loops in antibodies. On experimental data, we show that state-of-the-art model building methods can fail and CryoBoltz, leveraging knowledge acquired from large-scale datasets of protein structures, can fit atomic models within minutes, saving hours of manual refinement. With the increasing availability of predicted structures as priors for cryo-EM model building, the principled validation of the resulting atomic models, especially those derived from lower resolution maps, remains an open question.

An important limitation of CryoBoltz is the limited stability of optimization, due to the multimodality of the likelihood  $p(\mathbf{y}|\mathbf{x})$ . This instability is mitigated by sampling several structures simultaneously and selecting the best fit a posteriori, but this comes at the cost of increased memory and time consumption. Importantly, CryoBoltz also relies on the base (unguided) model being able to provide a good initialization during the “warm-up” stage, which we found not to be the case on several systems (e.g., DSL1/SNARE complex [19], full IgG antibody [67]). Future directions for this work therefore include exploring ways to stabilize guidance, mitigating the drift towards “off-manifold” regions (where the diffusion model is highly inaccurate), or getting rid of heuristic choices like the specific duration of each guidance stage. Finally, when having access to  $N$  cryo-EM maps, associated with






Figure 6: **Results on Pma1, CYP102A1, and YbbAP [56].** Cryoboltz guides the atomic model into two distinct conformations per complex based on experimental density maps.

similar conformations, exploring the possibility to optimize a unique deformation model instead of  $N$  independent models constitutes an interesting avenue for future work.

**Conclusion.** In this study, we demonstrate the possibility of increasing the sample diversity of state-of-the-art generative models using experimental cryo-EM data. Doing so, we hope to contribute to the ongoing community effort towards efficiently exploring the conformational landscape of macromolecules with machine learning models.

## Acknowledgements

The authors acknowledge the use of computing resources at Princeton Research Computing, a consortium of groups led by the Princeton Institute for Computational Science and Engineering (PICSciE) and Office of Information Technology's Research Computing. The Zhong lab is grateful for support from the Princeton Catalysis Initiative, Princeton School of Engineering and Applied Sciences, Chan Zuckerberg Imaging Institute, Janssen Pharmaceuticals, and Generate Biomedicines. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

## References

- [1] Josh Abramson, Jonas Adler, Jack Dunger, Richard Evans, Tim Green, Alexander Pritzel, Olaf Ronneberger, Lindsay Willmore, Andrew J Ballard, Joshua Bambrick, et al. Accurate structure prediction of biomolecular interactions with alphafold 3. *Nature*, 630(8016):493–500, 2024.
- [2] Brian DO Anderson. Reverse-time diffusion equation models. *Stochastic Processes and their Applications*, 12(3):313–326, 1982.

- [3] Minkyung Baek, Frank DiMaio, Ivan Anishchenko, Justas Dauparas, Sergey Ovchinnikov, Gyu Rie Lee, Jue Wang, Qian Cong, Lisa N Kinch, R Dustin Schaeffer, et al. Accurate prediction of protein structures and interactions using a three-track neural network. *Science*, 373(6557):871–876, 2021.
- [4] L. Bavnhoj, P.A. Paulsen, J.C. Flores-Canales, B. Schiott, and B.P. Pedersen. Sugar/h<sup>+</sup> symporter stp10 in outward occluded conformation, 2021.
- [5] L. Bavnhoj, P.A. Paulsen, J.C. Flores-Canales, B. Schiott, and B.P. Pedersen. Sugar/h<sup>+</sup> symporter stp10 in inward open conformation, 2021.
- [6] Laust Bavnhoj, Peter Aasted Paulsen, Jose C. Flores-Canales, Birgit Schiøtt, and Bjørn Panyella Pedersen. Molecular mechanism of sugar transport in plants unveiled by structures of glucose/h<sup>+</sup> symporter stp10. *Nature plants*, 7(10):1409–1419, 2021.
- [7] Helen Berman, Kim Henrick, and Haruki Nakamura. Announcing the worldwide protein data bank. *Nature structural & molecular biology*, 10(12):980–980, 2003.
- [8] Helen Berman, Kim Henrick, Haruki Nakamura, and John L Markley. The worldwide protein data bank (wwpdb): ensuring a single, uniform archive of pdb data. *Nucleic acids research*, 35 (suppl\_1):D301–D303, 2007.
- [9] Peter Brüggeller and Erwin Mayer. Complete vitrification in pure liquid water and dilute aqueous solutions. *Nature*, 288(5791):569–571, 1980.
- [10] Muyuan Chen and Steven J Ludtke. Deep learning-based mixed-dimensional gaussian mixture model for characterizing variability in cryo-em. *Nature methods*, 18(8):930–936, 2021.
- [11] Jooyoung Choi, Sungwon Kim, Yonghyun Jeong, Youngjune Gwon, and Sungroh Yoon. Ilvr: Conditioning method for denoising diffusion probabilistic models. *arXiv preprint arXiv:2108.02938*, 2021.
- [12] Hyungjin Chung, Jeongsol Kim, Michael T Mccann, Marc L Klasky, and Jong Chul Ye. Diffusion posterior sampling for general noisy inverse problems. *arXiv preprint arXiv:2209.14687*, 2022.
- [13] Kevin Cowtan. The buccaneer software for automated model building. 1. tracing protein chains. *Acta crystallographica section D: biological crystallography*, 62(9):1002–1011, 2006.
- [14] A.T. Culbertson and M. Liao. Cryo-em of human p-glycoprotein reveals an intermediate occluded conformation during active drug transport. *Nature Communications*, 16:3619, 2025. doi: 10.1038/s41467-025-58561-4.
- [15] A.T. Culbertson and M. Liao. Cryoem structure of p-glycoprotein in apo state, 2025.
- [16] A.T. Culbertson and M. Liao. Cryoem structure of p-glycoprotein in collapsed closed state under continuous turnover conditions with verapamil, 2025.
- [17] A.T. Culbertson and M. Liao. Cryoem structure of p-glycoprotein in occluded closed state under continuous turnover conditions with verapamil, 2025.
- [18] A.T. Culbertson and M. Liao. Cryoem structure of p-glycoprotein in inward facing 2 state under continuous turnover conditions with verapamil, 2025.
- [19] Kevin A DAmico, Abigail E Stanton, Jaden D Shirkey, Sophie M Travis, Philip D Jeffrey, and Frederick M Hughson. Structure of a membrane tethering complex incorporating multiple snares. *Nature structural & molecular biology*, 31(2):246–254, 2024.
- [20] Giannis Daras, Hyungjin Chung, Chieh-Hsin Lai, Yuki Mitsufuji, Jong Chul Ye, Peyman Milanfar, Alexandros G Dimakis, and Mauricio Delbracio. A survey on diffusion models for inverse problems. *arXiv preprint arXiv:2410.00083*, 2024.



- [21] Fatima A Davila-Hernandez, Biao Jin, Harley Pyles, Shuai Zhang, Zheming Wang, Timothy F Huddy, Asim K Bera, Alex Kang, Chun-Long Chen, James J De Yoreo, et al. Directing polymorph specific calcium carbonate formation with de novo protein templates. *Nature Communications*, 14(1):8191, 2023.
- [22] Marc De Graef. *Introduction to conventional transmission electron microscopy*. Cambridge university press, 2003.
- [23] Diego Del Alamo, Davide Sala, Hassane S Mchaourab, and Jens Meiler. Sampling alternative conformational states of transporters and receptors with alphafold2. *Elife*, 11:e75751, 2022.
- [24] J Dubochet and AW McDowell. Vitrification of pure water for electron microscopy. *Journal of microscopy*, 124(3):3–4, 1981.
- [25] Sasha B Ebrahimi and Devleena Samanta. Engineering protein-based therapeutics through structural and chemical design. *Nature Communications*, 14(1):2411, 2023.
- [26] Bradley Efron. Tweedie’s formula and selection bias. *Journal of the American Statistical Association*, 106(496):1602–1614, 2011.
- [27] Dominika Elmlund and Hans Elmlund. Simple: Software for ab initio reconstruction of heterogeneous single-particles. *Journal of structural biology*, 180(3):420–427, 2012.
- [28] Alisia Fadini, Minhuan Li, Airlie J McCoy, Thomas C Terwilliger, Randy J Read, Doeke Hekstra, and Mohammed AlQuraishi. Alphafold as a prior: Experimental structure determination conditioned on a pretrained neural network. *bioRxiv*, pages 2025–02, 2025.
- [29] AR Faruqi and R Henderson. Electronic detectors for electron microscopy. *Current opinion in structural biology*, 17(5):549–555, 2007.
- [30] Berthy T Feng, Jamie Smith, Michael Rubinstein, Huiwen Chang, Katherine L Bouman, and William T Freeman. Score-based diffusion models as principled priors for inverse imaging. In *Proceedings of the IEEE/CVF International Conference on Computer Vision*, pages 10520–10531, 2023.
- [31] Jean Feydy, Pierre Roussillon, Alain Trouvé, and Pietro Gori. Fast and scalable optimal transport for brain tractograms. In *Medical Image Computing and Computer Assisted Intervention – MICCAI 2019: 22nd International Conference, Shenzhen, China, October 13–17, 2019, Proceedings, Part III*, page 636–644, Berlin, Heidelberg, 2019. Springer-Verlag. ISBN 978-3-030-32247-2. doi: 10.1007/978-3-030-32248-9\_71.
- [32] Nabin Giri and Jianlin Cheng. De novo atomic protein structure modeling for cryoem density maps using 3d transformer and hmm. *Nature Communications*, 15(1):5511, 2024.
- [33] Theo Hahn, Uri Shmueli, and JC Wilson Arthur. *International tables for crystallography*, volume 1. Reidel Dordrecht, 1983.
- [34] Ulrich G Haussmann and Etienne Pardoux. Time reversal of diffusions. *The Annals of Probability*, pages 1188–1205, 1986.
- [35] Jiahua He, Peicong Lin, Ji Chen, Hong Cao, and Sheng-You Huang. Model building of protein complexes from intermediate-resolution cryo-em maps with deep learning-guided automatic assembly. *Nature Communications*, 13(1):4066, 2022.
- [36] Lim Heo and Michael Feig. Multi-state modeling of g-protein coupled receptors at experimental accuracy. *Proteins: Structure, Function, and Bioinformatics*, 90(11):1873–1885, 2022.
- [37] John B. Ingraham, Max Baranov, Zak Costello, Karl W. Barber, Wujie Wang, Ahmed Ismail, Vincent Frappier, Dana M. Lord, Christopher Ng-Thow-Hing, Erik R. Van Vlack, Shan Tie, Vincent Xue, Sarah C. Cowles, Alan Leung, João V. Rodrigues, Claudio L. Morales-Perez, Alex M. Ayoub, Robin Green, Katherine Puentes, Frank Oplinger, Nishant V. Panwar, Fritz Obermeyer, Adam R. Root, Andrew L. Beam, Frank J. Poelwijk, and Gevorg Grigoryan. Illuminating protein space with a programmable generative model. *Nature*, 623(7989):1070–1078, Nov 2023. ISSN 1476-4687. doi: 10.1038/s41586-023-06728-8.

- [38] Ajil Jalal, Marius Arvinte, Giannis Daras, Eric Price, Alexandros G Dimakis, and Jon Tamir. Robust compressed sensing mri with deep generative priors. *Advances in Neural Information Processing Systems*, 34:14938–14954, 2021.
- [39] Kiarash Jamali, Lukas Käll, Rui Zhang, Alan Brown, Dari Kimanius, and Sjors HW Scheres. Automated model building and protein identification in cryo-em maps. *Nature*, pages 1–2, 2024.
- [40] Bowen Jing, Bonnie Berger, and Tommi Jaakkola. Alphafold meets flow matching for generating protein ensembles. *arXiv preprint arXiv:2402.04845*, 2024.
- [41] John Jumper, Richard Evans, Alexander Pritzel, Tim Green, Michael Figurnov, Olaf Ronneberger, Kathryn Tunyasuvunakool, Russ Bates, Augustin Žídek, Anna Potapenko, et al. Highly accurate protein structure prediction with alphafold. *nature*, 596(7873):583–589, 2021.
- [42] W. Kabsch. A solution for the best rotation to relate two sets of vectors. *Acta Crystallographica Section A*, 32(5):922–923, 1976. doi: <https://doi.org/10.1107/S0567739476001873>.
- [43] Yogesh Kalakoti and Björn Wallner. Afsample2 predicts multiple conformations and ensembles with alphafold2. *Communications Biology*, 8(1):373, 2025.
- [44] Satinder Kaur, Josue Gomez-Blanco, Ahmad AZ Khalifa, Swathi Adinarayanan, Ruben Sanchez-Garcia, Daniel Wrapp, Jason S McLellan, Khanh Huy Bui, and Javier Vargas. Local computational methods to improve the interpretability and analysis of cryo-em maps. *Nature communications*, 12(1):1240, 2021.
- [45] Bahjat Kawar, Gregory Vaksman, and Michael Elad. Snips: Solving noisy inverse problems stochastically. *Advances in Neural Information Processing Systems*, 34:21757–21769, 2021.
- [46] Bahjat Kawar, Michael Elad, Stefano Ermon, and Jiaming Song. Denoising diffusion restoration models. *Advances in Neural Information Processing Systems*, 35:23593–23606, 2022.
- [47] Werner Kühlbrandt. The resolution revolution. *Science*, 343(6178):1443–1444, 2014.
- [48] Axel Levy, Eric R Chan, Sara Fridovich-Keil, Frédéric Poitevin, Ellen D Zhong, and Gordon Wetzstein. Solving inverse problems in protein space using diffusion-based priors. *arXiv preprint arXiv:2406.04239*, 2024.
- [49] Axel Levy, Rishwanth Raghu, J Ryan Feathers, Michal Grzadkowski, Frédéric Poitevin, Jake D Johnston, Francesca Vallese, Oliver Biggs Clarke, Gordon Wetzstein, and Ellen D Zhong. End-to-end neural ab initio reconstruction of challenging cryo-em and cryo-et datasets. *bioRxiv*, pages 2024–05, 2024.
- [50] Sarah Lewis, Tim Hempel, José Jiménez-Luna, Michael Gastegger, Yu Xie, Andrew YK Foong, Victor García Satorras, Osama Abidin, Bastiaan S Veeling, Iryna Zaporozhets, et al. Scalable emulation of protein equilibrium ensembles with generative deep learning. *bioRxiv*, pages 2024–12, 2024.
- [51] Dorothee Liebschner, Pavel V Afonine, Matthew L Baker, Gábor Bunkóczi, Vincent B Chen, Tristan I Croll, Bradley Hintze, L-W Hung, Swati Jain, Airlie J McCoy, et al. Macromolecular structure determination using x-rays, neutrons and electrons: recent developments in phenix. *Acta Crystallographica Section D: Structural Biology*, 75(10):861–877, 2019.
- [52] Zeming Lin, Halil Akin, Roshan Rao, Brian Hie, Zhongkai Zhu, Wenting Lu, Nikita Smetanin, Robert Verkuil, Ori Kabeli, Yaniv Shmueli, et al. Evolutionary-scale prediction of atomic-level protein structure with a language model. *Science*, 379(6637):1123–1130, 2023.
- [53] Advait Maddipatla, Nadav Bojan Sellam, Meital Bojan, Sanketh Vedula, Paul Schanda, Ailie Marx, and Alex M Bronstein. Inverse problems with experiment-guided alphafold. *arXiv preprint arXiv:2502.09372*, 2025.
- [54] Sai Advait Maddipatla, Nadav Bojan Sellam, Sanketh Vedula, Ailie Marx, and Alex Bronstein. Generative modeling of protein ensembles guided by crystallographic electron densities. *arXiv preprint arXiv:2412.13223*, 2024.

- [55] Morteza Mardani, Jiaming Song, Jan Kautz, and Arash Vahdat. A variational perspective on solving inverse problems with diffusion models. *arXiv preprint arXiv:2305.04391*, 2023.
- [56] Martin B.L. McAndrew, Jonathan Cook, Amy Gill, Kavya Sahoo, Clare Thomas, Phillip J. Stansfeld, and Allister Crow. Structure of ybbap-tesa: a type vii abc transporter–lipid hydrolase complex. *bioRxiv*, 2025. doi: 10.1101/2025.05.16.654284.
- [57] M.B. McAndrew, J. Cook, A. Gill, K. Sahoo, C. Thomas, P.J. Stansfeld, and A. Crow. Structure of e. coli ybbap, 2025.
- [58] M.B. McAndrew, J. Cook, A. Gill, K. Sahoo, C. Thomas, P.J. Stansfeld, and A. Crow. Structure of e. coli ybbap with bound atp analogue, 2025.
- [59] Elaine C. Meng, Thomas D. Goddard, Eric F. Pettersen, Greg S. Couch, Zach J. Pearson, John H. Morris, and Thomas E. Ferrin. Ucsf chimeraX: Tools for structure building and analysis. *Protein Science*, 32(11):e4792, 2023. doi: <https://doi.org/10.1002/pro.4792>.
- [60] Gabriel Peyré, Marco Cuturi, et al. Computational optimal transport: With applications to data science. *Foundations and Trends® in Machine Learning*, 11(5-6):355–607, 2019.
- [61] Jonas Pfab, Nhut Minh Phan, and Dong Si. Deeptimizer for fast de novo cryo-em protein structure modeling and special studies on cov-related complexes. *Proceedings of the National Academy of Sciences*, 118(2):e2017525118, 2021.
- [62] Ali Punjani and David J Fleet. 3d variability analysis: Resolving continuous flexibility and discrete heterogeneity from single particle cryo-em. *Journal of structural biology*, 213(2): 107702, 2021.
- [63] Ali Punjani and David J Fleet. 3dflex: determining structure and motion of flexible proteins from cryo-em. *Nature Methods*, 20(6):860–870, 2023.
- [64] Ali Punjani, John L Rubinstein, David J Fleet, and Marcus A Brubaker. cryosparc: algorithms for rapid unsupervised cryo-em structure determination. *Nature methods*, 14(3):290–296, 2017.
- [65] Alexander Rives, Joshua Meier, Tom Sercu, Siddharth Goyal, Zeming Lin, Jason Liu, Demi Guo, Myle Ott, C Lawrence Zitnick, Jerry Ma, et al. Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences. *Proceedings of the National Academy of Sciences*, 118(15):e2016239118, 2021.
- [66] Herbert E Robbins. An empirical bayes approach to statistics. In *Breakthroughs in Statistics: Foundations and basic theory*, pages 388–394. Springer, 1992.
- [67] Erica Ollmann Saphire, Paul WHI Parren, Ralph Pantophlet, Michael B Zwick, Garrett M Morris, Pauline M Rudd, Raymond A Dwek, Robyn L Stanfield, Dennis R Burton, and Ian A Wilson. Crystal structure of a neutralizing human igg against hiv-1: a template for vaccine design. *science*, 293(5532):1155–1159, 2001.
- [68] Sjors HW Scheres. Relion: implementation of a bayesian approach to cryo-em structure determination. *Journal of structural biology*, 180(3):519–530, 2012.
- [69] Sjors HW Scheres, Haixiao Gao, Mikel Valle, Gabor T Herman, Paul PB Eggermont, Joachim Frank, and Jose-Maria Carazo. Disentangling conformational states of macromolecules in 3d-em through likelihood optimization. *Nature methods*, 4(1):27–29, 2007.
- [70] Aaron G. Schmidt, Huafeng Xu, Amir R. Khan, Timothy O’Donnell, Surender Khurana, Lisa R. King, Jody Manischewitz, Hana Golding, Pirada Suphaphiphat, Andrea Carfi, Ethan C. Settembre, Philip R. Dormitzer, Thomas B. Kepler, Ruijun Zhang, M. Anthony Moody, Barton F. Haynes, Hua-Xin Liao, David E. Shaw, and Stephen C. Harrison. Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. *Proceedings of the National Academy of Sciences*, 110(1):264–269, 2013. doi: 10.1073/pnas.1218256109.

- [71] A.G. Schmidt, H. Xu, A.R. Khan, T. O'Donnell, S. Khurana, L.R. King, J. Manischewitz, H. Golding, P. Suphaphiphat, A. Carfi, E.C. Settembre, P.R. Dormitzer, T.B. Kepler, R. Zhang, M.A. Moody, B.F. Haynes, H.X. Liao, D.E. Shaw, and S.C. Harrison. Influenza hemagglutinin in complex with ch67 fab, 2012.
- [72] Dong Si, Spencer A Moritz, Jonas Pfab, Jie Hou, Renzhi Cao, Ligu Wang, Tianqi Wu, and Jianlin Cheng. Deep learning to predict protein backbone structure from high-resolution cryo-em density maps. *Scientific reports*, 10(1):4282, 2020.
- [73] Abhishek Singharoy, Ivan Teo, Ryan McGreevy, John E Stone, Jianhua Zhao, and Klaus Schulten. Molecular dynamics-based refinement and validation for sub-5 Å cryo-electron microscopy maps. *Elife*, 5:e16105, 2016.
- [74] Jiaming Song, Arash Vahdat, Morteza Mardani, and Jan Kautz. Pseudoinverse-guided diffusion models for inverse problems. In *International Conference on Learning Representations*, 2023.
- [75] Yang Song, Jascha Sohl-Dickstein, Diederik P Kingma, Abhishek Kumar, Stefano Ermon, and Ben Poole. Score-based generative modeling through stochastic differential equations. *arXiv preprint arXiv:2011.13456*, 2020.
- [76] Yang Song, Conor Durkan, Iain Murray, and Stefano Ermon. Maximum likelihood training of score-based diffusion models. *Advances in neural information processing systems*, 34: 1415–1428, 2021.
- [77] Charles M Stein. Estimation of the mean of a multivariate normal distribution. *The annals of Statistics*, pages 1135–1151, 1981.
- [78] M. Su and H. Xu. Cyp102a1 in open conformation, 2023.
- [79] M. Su and H. Xu. Cyp102a1 in closed conformation, 2023.
- [80] Kenneth A Taylor and Robert M Glaeser. Electron diffraction of frozen, hydrated protein crystals. *Science*, 186(4168):1036–1037, 1974.
- [81] Genki Terashi and Daisuke Kihara. De novo main-chain modeling for em maps using mainmast. *Nature communications*, 9(1):1618, 2018.
- [82] Thomas C Terwilliger, Paul D Adams, Pavel V Afonine, and Oleg V Sobolev. A fully automatic method yielding initial models from high-resolution cryo-electron microscopy maps. *Nature methods*, 15(11):905–908, 2018.
- [83] Ian J. Tickle. Statistical quality indicators for electron-density maps. *Acta Crystallographica Section D*, 68(4):454–467, Apr 2012. doi: 10.1107/S0907444911035918.
- [84] Pascal Vincent. A connection between score matching and denoising autoencoders. *Neural computation*, 23(7):1661–1674, 2011.
- [85] Ray Yu-Ruei Wang, Mikhail Kudryashev, Xueming Li, Edward H Egelman, Marek Basler, Yifan Cheng, David Baker, and Frank DiMaio. De novo protein structure determination from near-atomic-resolution cryo-em maps. *Nature methods*, 12(4):335–338, 2015.
- [86] Yinhuai Wang, Jiwen Yu, and Jian Zhang. Zero-shot image restoration using denoising diffusion null-space model. *arXiv preprint arXiv:2212.00490*, 2022.
- [87] Hannah K Wayment-Steele, Adedolapo Ojoawo, Renee Otten, Julia M Apitz, Warintra Pit-sawong, Marc Hömberger, Sergey Ovchinnikov, Lucy Colwell, and Dorothee Kern. Predicting multiple conformations via sequence clustering and alphafold2. *Nature*, 625(7996):832–839, 2024.
- [88] Jeremy Wohlwend, Gabriele Corso, Saro Passaro, Noah Getz, Mateo Reveiz, Ken Leidal, Wojtek Swiderski, Liam Atkinson, Tally Portnoi, Itamar Chinn, Jacob Silterra, Tommi Jaakkola, and Regina Barzilay. Boltz-1: Democratizing biomolecular interaction modeling. *bioRxiv*, 2024. doi: 10.1101/2024.11.19.624167.

- [89] Z.L. You and L. Bai. Cryo-em structure of the pma1 with ordered n-terminal extension in the activated state, 2025.
- [90] Z.L. You and L. Bai. Cryo-em structure of the pma1 with ordered n-terminal extension in the autoinhibited state, 2025.
- [91] Bingliang Zhang, Wenda Chu, Julius Berner, Chenlin Meng, Anima Anandkumar, and Yang Song. Improving diffusion inverse problem solving with decoupled noise annealing. *arXiv preprint arXiv:2407.01521*, 2024.
- [92] Xi Zhang, Biao Zhang, Peter L Freddolino, and Yang Zhang. Cr-i-tasser: assemble protein structures from cryo-em density maps using deep convolutional neural networks. *Nature methods*, 19(2):195–204, 2022.
- [93] Yang Zhang and Jeffrey Skolnick. Tm-align: a protein structure alignment algorithm based on the tm-score. *Nucleic Acids Research*, 33(7):2302–2309, 01 2005. ISSN 0305-1048. doi: 10.1093/nar/gki524.
- [94] Ellen D Zhong, Tristan Bepler, Bonnie Berger, and Joseph H Davis. Cryodrgn: reconstruction of heterogeneous cryo-em structures using neural networks. *Nature methods*, 18(2):176–185, 2021.

## Appendix

### A Supplemental Methods

#### A.1 Point cloud construction

For global guidance, the input density map is converted to a point cloud by performing weighted  $k$ -means clustering on the voxel coordinates, where the weights are given by the map intensity values.  $k$  is set to  $\lfloor N/(4r^3) \rfloor$ , where  $N$  is the number of atoms in the system and  $r$  is the voxel size of the map in Å. Prior to clustering, density values below a threshold may be set to 0, and connected density components below a size threshold may be removed ("dusted"). See Experimental Details for dataset-dependent values, where applicable.

#### A.2 Simulated map construction

For local guidance, a density map is simulated from the sample using a single Gaussian per atom whose amplitude is given by atomic number, as implemented in the default *molmap* function of ChimeraX [59]. The map is simulated to match the voxel size and nominal resolution of the input map.

#### A.3 Alignment to density map

For efficient optimization of the point cloud guidance term, the intermediate sample must be aligned to the input density map. We obtain an unguided sample and dock it into the map using the ChimeraX *fitmap* function [59]. Prior to the first step of guidance, the intermediate sample is aligned to the unguided sample via the Kabsch algorithm [42].

#### A.4 Sinkhorn divergence

For two point clouds  $X \in \mathbb{R}^{N \times 3}$  and  $Y \in \mathbb{R}^{M \times 3}$ , the entropy-regularized optimal transport distance is given by

$$\text{OT}_\epsilon(X, Y) = \min_{\gamma \in \mathbb{R}_+^{N \times M}} \sum_i \sum_j^N \gamma_{ij} C_{ij} - \epsilon \sum_i \sum_j^N \gamma_{ij} \log \gamma_{ij}$$

where  $\gamma$  is a *transport plan* whose rows each sum to  $1/N$  and columns each sum to  $1/M$ . The first term is the Wasserstein distance between the point clouds, where the cost  $C_{ij}$  between two points is the squared Euclidean distance  $\frac{1}{2} \|X_i - Y_j\|_2^2$ . The second term is the entropy of  $\gamma$ , which allows for tractable and differentiable optimization and is controlled by the regularization strength  $\epsilon$ . As the entropy term introduces an approximation error to the true Wasserstein distance, the Sinkhorn divergence corrects for this and is defined as

$$\mathfrak{D}(X, Y) = \text{OT}_\epsilon(X, Y) - \frac{1}{2} \text{OT}_\epsilon(X, X) - \frac{1}{2} \text{OT}_\epsilon(Y, Y)$$

We use the GeomLoss library for efficient optimization of the objective  $\mathfrak{D}$  with respect to the sample coordinates [31]. The *reach* parameter is set to 10 while all others are set to their defaults.

#### A.5 Guidance schedule

For the synthetic datasets, the numbers of steps in the guidance phases are  $T_w = 125$ ,  $T_g = 25$ ,  $T_l = 25$ , and  $T_r = 25$ . For the experimental datasets, the numbers of steps are  $T_w = 100$ ,  $T_g = 50$ ,  $T_l = 25$ , and  $T_r = 25$ . During the global guidance phase (for all datasets), the guidance strength is annealed along a cosine schedule from 0.25 to 0.05, i.e.,  $\lambda(t) = 0.05 + \frac{1}{2}(0.25 - 0.05)(1 + \cos(\frac{\pi t}{T_g}))$ . During the local guidance phase, the guidance strength is made constant at  $\lambda(t) = 0.5$ .

#### A.6 Experimental Details

**STP10.** Deposited structures of the inward and outward conformations (PDB: 7AAQ, 7AAR) [4, 5] were stripped of non-protein entities. Synthetic density maps of 2 Å resolution and 1 Å voxel size were



generated using the ChimeraX *molmap* function [59], then padded to dimension  $w = h = d = 100$ . The wild-type protein sequence corresponding to PDB:7AAQ was given as input.

**CH67 Antibody.** The deposited structure of the antibody Fab (PDB:4HKX) was stripped of non-protein entities and the bound hemagglutinin receptor. A synthetic density map of 4 Å resolution and 1 Å voxel size was generated and padded to dimension  $w = h = d = 100$ . For CryoBoltz and Boltz-1 [88], the *step\_scale* parameter, which controls the temperature of the sampling distribution, is set at 3.0 to increase CDR H3 loop accuracy.

**P-glycoprotein.** The experimental maps of four conformational states (EMD-40226, 40259, 40258, 40227) were masked around their corresponding deposited models (PDB:8GMG, 8SA1, 8SA0, 8GMJ) [15–18] to remove micelle density, using the ChimeraX *volume zone* function [59]. A padding of 5 voxels was then added to each side.

**Pma1.** The experimental maps of two conformational states (EMD-64135, 64136) were cropped to a tight box at a density threshold of 0.35 then padded by 10 voxels on each side. This removed empty background regions for computational efficiency. During the global guidance phase of the method, the maps were thresholded at a value of 0.35.

**CYP102A1.** The experimental maps of two conformational states (EMD-27534, 27536) were cropped to a tight box at a density threshold of 1.25 then padded by 10 voxels on each side. During the global guidance phase of the method, the maps were thresholded at a value of 1.25.

**YbbAP.** The experimental maps of two conformational states (EMD-51292, 51291) were cropped to a tight box at a density threshold of 0.005 then padded by 10 voxels on each side. During the global guidance phase of the method, the maps were thresholded at a value of 0.005, and dusted with size threshold 100.

## A.7 Computational resources

All experiments were performed on a single Nvidia A100 GPU with 80 GB VRAM.

## B Supplemental Results

### B.1 Map-model fit and statistical significance

In Table B2, we report evaluation metrics and confidence bounds on the best generated sample as assessed by map-model fit. Three replicates of each method are run to produce 25 samples per replicate. Samples are ranked according to the real-space correlation coefficient (RSCC), which is the Pearson correlation between the input density map and a map simulated from the sample [83]. For the unguided baselines, we first align each sample to the deposited model via the Kabsch algorithm [42]. CryoBoltz demonstrates statistically significant improvement over baselines across a majority of maps and metrics.

### B.2 Spread of sample quality

In Figures B2 and B3, we visualize the full distribution of RMSD values over all samples produced by CryoBoltz, Boltz-1 and AlphaFold3. For nearly all maps, a majority of CryoBoltz samples are more accurate than those produced by the baselines.

Table B1: **Additional baselines and ablations for experimental cryo-EM density maps.** Extending Table 2, we report accuracy metrics for MSA subsampling of Boltz-1, as well as ablations of the local and global guidance phases. We report the mean all-atom RMSD (Å), C $\alpha$  RMSD (Å) and TM score for the best of 25 samples (lowest all-atom RMSD) across 3 model replicates. Random MSA subsampling of Boltz-1 (Boltz-1 + MSA sub.) is run with MSA depths of 64, 128, 256, 512, and 1024, each producing 5 samples. Pgp is P-glycoprotein and CYP is CYP201A1. **Bold** indicates best value(s).

| Structure        | CryoBoltz    |                 |              | Boltz-1 + MSA subsampling |                 |          | Local only |                 |          | Global only  |                 |              |
|------------------|--------------|-----------------|--------------|---------------------------|-----------------|----------|------------|-----------------|----------|--------------|-----------------|--------------|
|                  | RMSD all     | RMSD C $\alpha$ | TM score     | RMSD all                  | RMSD C $\alpha$ | TM score | RMSD all   | RMSD C $\alpha$ | TM score | RMSD all     | RMSD C $\alpha$ | TM score     |
| Pgp (apo)        | <b>1.382</b> | <b>1.208</b>    | <b>0.989</b> | 6.902                     | 7.099           | 0.770    | 5.897      | 6.026           | 0.810    | 1.501        | 1.335           | 0.986        |
| Pgp (inward)     | <b>1.348</b> | <b>1.187</b>    | <b>0.989</b> | 5.541                     | 5.601           | 0.831    | 4.416      | 4.438           | 0.878    | 1.369        | 1.252           | 0.988        |
| Pgp (occluded)   | 1.727        | 1.677           | <b>0.979</b> | 2.875                     | 2.847           | 0.945    | 1.916      | 1.882           | 0.974    | <b>1.714</b> | <b>1.673</b>    | 0.979        |
| Pgp (collapsed)  | <b>1.309</b> | <b>1.261</b>    | <b>0.988</b> | 3.497                     | 3.482           | 0.914    | 1.781      | 1.754           | 0.977    | 1.453        | 1.424           | 0.984        |
| Pma1 (active)    | <b>2.046</b> | <b>1.776</b>    | <b>0.973</b> | 3.204                     | 2.935           | 0.927    | 3.228      | 2.938           | 0.930    | 2.164        | 1.907           | 0.967        |
| Pma1 (inhibited) | <b>1.999</b> | <b>1.590</b>    | <b>0.979</b> | 7.444                     | 7.156           | 0.745    | 7.299      | 6.974           | 0.751    | 2.223        | 1.829           | 0.971        |
| CYP (open)       | 4.167        | 3.946           | 0.957        | 11.971                    | 11.868          | 0.635    | 8.342      | 8.242           | 0.804    | <b>3.918</b> | <b>3.720</b>    | <b>0.959</b> |
| CYP (closed)     | <b>2.004</b> | <b>1.552</b>    | <b>0.990</b> | 13.395                    | 13.262          | 0.594    | 6.132      | 5.986           | 0.857    | 2.089        | 1.763           | 0.987        |
| YbbAP (bound)    | <b>1.320</b> | <b>0.678</b>    | <b>0.997</b> | 3.586                     | 3.273           | 0.931    | 3.625      | 3.360           | 0.926    | 1.695        | 1.161           | 0.991        |
| YbbAP (unbound)  | <b>2.454</b> | <b>2.039</b>    | <b>0.974</b> | 5.254                     | 4.992           | 0.865    | 7.069      | 6.825           | 0.823    | 2.762        | 2.400           | 0.964        |

Table B2: **Evaluation of samples chosen by map-model fit.** We report the Root Mean Square Deviation (RMSD) for all atoms, the C $\alpha$  RMSD, the template-modeling (TM) score, and the real-space correlation coefficient (RSCC). For CH67, we also report the RMSD for the C $\alpha$  atoms in the CDR H3 loop (local RMSD). The mean and 95% confidence interval across 3 replicates are reported for the best of 25 samples as assessed by map fit (highest RSCC). **Bold** indicates (statistically significant) best value(s).

| Structure               | Metrics                | CryoBoltz                  | Boltz-1             | AlphaFold3                 |
|-------------------------|------------------------|----------------------------|---------------------|----------------------------|
| STP10 (inward)          | RMSD (Å, ↓)            | <b>1.1756</b> $\pm$ 0.0859 | 3.8313 $\pm$ 0.0810 | 1.3250 $\pm$ 0.0216        |
|                         | C $\alpha$ RMSD (Å, ↓) | <b>0.4776</b> $\pm$ 0.0262 | 3.5838 $\pm$ 0.0913 | 0.6543 $\pm$ 0.0248        |
|                         | TM score (↑)           | <b>0.9969</b> $\pm$ 0.0002 | 0.8620 $\pm$ 0.0043 | 0.9939 $\pm$ 0.0003        |
|                         | RSCC (↑)               | <b>0.8525</b> $\pm$ 0.0043 | 0.2402 $\pm$ 0.0031 | 0.7343 $\pm$ 0.0029        |
| STP10 (outward)         | RMSD                   | <b>0.9090</b> $\pm$ 0.0308 | 2.6596 $\pm$ 0.0039 | 4.4777 $\pm$ 0.0244        |
|                         | C $\alpha$ RMSD        | <b>0.4670</b> $\pm$ 0.0613 | 2.4203 $\pm$ 0.0102 | 4.2283 $\pm$ 0.0369        |
|                         | TM score               | <b>0.9971</b> $\pm$ 0.0006 | 0.9485 $\pm$ 0.0004 | 0.8276 $\pm$ 0.0022        |
|                         | RSCC                   | <b>0.8862</b> $\pm$ 0.0064 | 0.5098 $\pm$ 0.0015 | 0.1946 $\pm$ 0.0011        |
| CH67 antibody           | RMSD                   | <b>1.2957</b> $\pm$ 0.2995 | 1.9940 $\pm$ 0.0810 | 1.9719 $\pm$ 0.1210        |
|                         | C $\alpha$ RMSD        | <b>0.8739</b> $\pm$ 0.2010 | 1.4970 $\pm$ 0.0418 | 1.4935 $\pm$ 0.0902        |
|                         | Local RMSD             | <b>1.3326</b> $\pm$ 1.0667 | 3.5518 $\pm$ 0.1133 | 3.9562 $\pm$ 0.4517        |
|                         | TM score               | <b>0.9917</b> $\pm$ 0.0027 | 0.9713 $\pm$ 0.0029 | 0.9708 $\pm$ 0.0035        |
|                         | RSCC                   | <b>0.9521</b> $\pm$ 0.0041 | 0.8452 $\pm$ 0.0155 | 0.8466 $\pm$ 0.0117        |
| P-glycoprotein (apo)    | RMSD                   | <b>1.4931</b> $\pm$ 0.0803 | 7.0928 $\pm$ 0.1115 | 3.8272 $\pm$ 1.4344        |
|                         | C $\alpha$ RMSD        | <b>1.3377</b> $\pm$ 0.1124 | 7.3054 $\pm$ 0.1164 | 3.8652 $\pm$ 1.5225        |
|                         | TM score               | <b>0.9876</b> $\pm$ 0.0004 | 0.7650 $\pm$ 0.0054 | 0.9036 $\pm$ 0.0611        |
|                         | RSCC                   | <b>0.8157</b> $\pm$ 0.0007 | 0.4261 $\pm$ 0.0033 | 0.5797 $\pm$ 0.0982        |
| P-glycoprotein (inward) | RMSD                   | <b>1.4311</b> $\pm$ 0.0346 | 5.6799 $\pm$ 0.1275 | 2.6923 $\pm$ 1.1995        |
|                         | C $\alpha$ RMSD        | <b>1.2828</b> $\pm$ 0.0407 | 5.7454 $\pm$ 0.1302 | 2.6634 $\pm$ 1.2533        |
|                         | TM score               | <b>0.9876</b> $\pm$ 0.0007 | 0.8293 $\pm$ 0.0056 | <b>0.9475</b> $\pm$ 0.0440 |
|                         | RSCC                   | <b>0.8165</b> $\pm$ 0.0011 | 0.5109 $\pm$ 0.0069 | 0.6927 $\pm$ 0.0884        |

|                               |                 |                        |                 |                        |
|-------------------------------|-----------------|------------------------|-----------------|------------------------|
| P-glycoprotein<br>(occluded)  | RMSD            | <b>1.8070</b> ± 0.0094 | 2.9844 ± 0.1159 | 3.4641 ± 0.0747        |
|                               | C $\alpha$ RMSD | <b>1.7505</b> ± 0.0080 | 2.9566 ± 0.1160 | 3.4429 ± 0.0738        |
|                               | TM score        | <b>0.9778</b> ± 0.0004 | 0.9402 ± 0.0041 | 0.9209 ± 0.0021        |
|                               | RSCC            | <b>0.7662</b> ± 0.0006 | 0.6191 ± 0.0072 | 0.5857 ± 0.0001        |
| P-glycoprotein<br>(collapsed) | RMSD            | <b>1.3881</b> ± 0.0349 | 3.4253 ± 0.2934 | 4.5681 ± 0.1824        |
|                               | C $\alpha$ RMSD | <b>1.3397</b> ± 0.0363 | 3.4117 ± 0.2929 | 4.5538 ± 0.1798        |
|                               | TM score        | <b>0.9860</b> ± 0.0007 | 0.9174 ± 0.0128 | 0.8642 ± 0.0084        |
|                               | RSCC            | <b>0.7884</b> ± 0.0012 | 0.5746 ± 0.0330 | 0.4904 ± 0.0108        |
| Pma1<br>(active)              | RMSD            | <b>2.1745</b> ± 0.3212 | 3.0098 ± 0.2575 | 6.6283 ± 1.0733        |
|                               | C $\alpha$ RMSD | <b>1.9144</b> ± 0.3517 | 2.7817 ± 0.2590 | 6.3890 ± 1.0764        |
|                               | TM score        | <b>0.9706</b> ± 0.0082 | 0.9352 ± 0.0114 | 0.7691 ± 0.0523        |
|                               | RSCC            | <b>0.5633</b> ± 0.0113 | 0.3540 ± 0.0234 | 0.2054 ± 0.0102        |
| Pma1<br>(inhibited)           | RMSD            | <b>2.0499</b> ± 0.1296 | 6.1404 ± 0.7005 | 8.2569 ± 0.5666        |
|                               | C $\alpha$ RMSD | <b>1.6640</b> ± 0.1413 | 5.8287 ± 0.7180 | 8.0042 ± 0.5289        |
|                               | TM score        | <b>0.9774</b> ± 0.0026 | 0.7943 ± 0.0339 | 0.7167 ± 0.0202        |
|                               | RSCC            | <b>0.5276</b> ± 0.0012 | 0.2439 ± 0.0246 | 0.2166 ± 0.0027        |
| CYP201A1<br>(open)            | RMSD            | <b>4.3939</b> ± 0.0988 | 8.5324 ± 0.1545 | 6.5074 ± 0.0836        |
|                               | C $\alpha$ RMSD | <b>4.1473</b> ± 0.0923 | 8.4389 ± 0.1539 | 6.3770 ± 0.0791        |
|                               | TM score        | <b>0.9535</b> ± 0.0013 | 0.7878 ± 0.0110 | 0.8912 ± 0.0036        |
|                               | RSCC            | <b>0.7693</b> ± 0.0013 | 0.5074 ± 0.0059 | 0.6220 ± 0.0043        |
| CYP201A1<br>(closed)          | RMSD            | <b>2.8636</b> ± 0.6566 | 8.7837 ± 0.3684 | <b>3.5848</b> ± 0.5770 |
|                               | C $\alpha$ RMSD | <b>2.4669</b> ± 0.7572 | 8.6674 ± 0.3758 | <b>3.3910</b> ± 0.6050 |
|                               | TM score        | <b>0.9868</b> ± 0.0022 | 0.7435 ± 0.0151 | 0.9459 ± 0.0186        |
|                               | RSCC            | <b>0.8062</b> ± 0.0002 | 0.4937 ± 0.0059 | 0.6830 ± 0.0338        |
| YbbAP<br>(bound)              | RMSD            | <b>1.3842</b> ± 0.0803 | 3.6264 ± 0.2116 | 3.7488 ± 0.1888        |
|                               | C $\alpha$ RMSD | <b>0.7578</b> ± 0.0892 | 3.3550 ± 0.2512 | 3.4802 ± 0.1897        |
|                               | TM score        | <b>0.9961</b> ± 0.0006 | 0.9283 ± 0.0092 | 0.9219 ± 0.0079        |
|                               | RSCC            | <b>0.7046</b> ± 0.0005 | 0.5074 ± 0.0116 | 0.4966 ± 0.0083        |
| YbbAP<br>(unbound)            | RMSD            | <b>3.8623</b> ± 0.6404 | 8.2798 ± 0.2012 | <b>4.0646</b> ± 0.4578 |
|                               | C $\alpha$ RMSD | <b>3.5271</b> ± 0.7067 | 8.0973 ± 0.2010 | <b>3.7913</b> ± 0.4791 |
|                               | TM score        | <b>0.9607</b> ± 0.0058 | 0.7751 ± 0.0066 | 0.9114 ± 0.0184        |
|                               | RSCC            | <b>0.7098</b> ± 0.0011 | 0.4944 ± 0.0111 | 0.5594 ± 0.0178        |




Figure B1: **Full CH67 antibody [70] structures generated by all methods.** Top 5 samples from each method, as ranked by all-atom RMSD.




Figure B2: **Distribution of RMSD values for synthetic maps.** All-atom RMSD values for all samples over all replicates are visualized as histograms with 50 bins.




Figure B3: **Distribution of RMSD values for experimental maps.** All-atom RMSD values for all samples over all replicates are visualized as histograms with 50 bins.

## NeurIPS Paper Checklist

### 1. Claims

Question: Do the main claims made in the abstract and introduction accurately reflect the paper's contributions and scope?

Answer: [Yes]

Justification: The claims and contributions are supported with experimental results in Section 4.

Guidelines:

- The answer NA means that the abstract and introduction do not include the claims made in the paper.
- The abstract and/or introduction should clearly state the claims made, including the contributions made in the paper and important assumptions and limitations. A No or NA answer to this question will not be perceived well by the reviewers.
- The claims made should match theoretical and experimental results, and reflect how much the results can be expected to generalize to other settings.
- It is fine to include aspirational goals as motivation as long as it is clear that these goals are not attained by the paper.

### 2. Limitations

Question: Does the paper discuss the limitations of the work performed by the authors?

Answer: [Yes]

Justification: Limitations are discussed in Section 5.

Guidelines:

- The answer NA means that the paper has no limitation while the answer No means that the paper has limitations, but those are not discussed in the paper.
- The authors are encouraged to create a separate "Limitations" section in their paper.
- The paper should point out any strong assumptions and how robust the results are to violations of these assumptions (e.g., independence assumptions, noiseless settings, model well-specification, asymptotic approximations only holding locally). The authors should reflect on how these assumptions might be violated in practice and what the implications would be.
- The authors should reflect on the scope of the claims made, e.g., if the approach was only tested on a few datasets or with a few runs. In general, empirical results often depend on implicit assumptions, which should be articulated.
- The authors should reflect on the factors that influence the performance of the approach. For example, a facial recognition algorithm may perform poorly when image resolution is low or images are taken in low lighting. Or a speech-to-text system might not be used reliably to provide closed captions for online lectures because it fails to handle technical jargon.
- The authors should discuss the computational efficiency of the proposed algorithms and how they scale with dataset size.
- If applicable, the authors should discuss possible limitations of their approach to address problems of privacy and fairness.
- While the authors might fear that complete honesty about limitations might be used by reviewers as grounds for rejection, a worse outcome might be that reviewers discover limitations that aren't acknowledged in the paper. The authors should use their best judgment and recognize that individual actions in favor of transparency play an important role in developing norms that preserve the integrity of the community. Reviewers will be specifically instructed to not penalize honesty concerning limitations.

### 3. Theory assumptions and proofs

Question: For each theoretical result, does the paper provide the full set of assumptions and a complete (and correct) proof?

Answer: [NA]

Justification: The paper does not include new theoretical results.

Guidelines:

- The answer NA means that the paper does not include theoretical results.
- All the theorems, formulas, and proofs in the paper should be numbered and cross-referenced.
- All assumptions should be clearly stated or referenced in the statement of any theorems.
- The proofs can either appear in the main paper or the supplemental material, but if they appear in the supplemental material, the authors are encouraged to provide a short proof sketch to provide intuition.
- Inversely, any informal proof provided in the core of the paper should be complemented by formal proofs provided in appendix or supplemental material.
- Theorems and Lemmas that the proof relies upon should be properly referenced.

#### 4. Experimental result reproducibility

Question: Does the paper fully disclose all the information needed to reproduce the main experimental results of the paper to the extent that it affects the main claims and/or conclusions of the paper (regardless of whether the code and data are provided or not)?

Answer: [\[Yes\]](#)

Justification: The method is described in Section 3 and implementation details are given in Section 4.1 and in the Appendix.

Guidelines:

- The answer NA means that the paper does not include experiments.
- If the paper includes experiments, a No answer to this question will not be perceived well by the reviewers: Making the paper reproducible is important, regardless of whether the code and data are provided or not.
- If the contribution is a dataset and/or model, the authors should describe the steps taken to make their results reproducible or verifiable.
- Depending on the contribution, reproducibility can be accomplished in various ways. For example, if the contribution is a novel architecture, describing the architecture fully might suffice, or if the contribution is a specific model and empirical evaluation, it may be necessary to either make it possible for others to replicate the model with the same dataset, or provide access to the model. In general, releasing code and data is often one good way to accomplish this, but reproducibility can also be provided via detailed instructions for how to replicate the results, access to a hosted model (e.g., in the case of a large language model), releasing of a model checkpoint, or other means that are appropriate to the research performed.
- While NeurIPS does not require releasing code, the conference does require all submissions to provide some reasonable avenue for reproducibility, which may depend on the nature of the contribution. For example
  - (a) If the contribution is primarily a new algorithm, the paper should make it clear how to reproduce that algorithm.
  - (b) If the contribution is primarily a new model architecture, the paper should describe the architecture clearly and fully.
  - (c) If the contribution is a new model (e.g., a large language model), then there should either be a way to access this model for reproducing the results or a way to reproduce the model (e.g., with an open-source dataset or instructions for how to construct the dataset).
  - (d) We recognize that reproducibility may be tricky in some cases, in which case authors are welcome to describe the particular way they provide for reproducibility. In the case of closed-source models, it may be that access to the model is limited in some way (e.g., to registered users), but it should be possible for other researchers to have some path to reproducing or verifying the results.

#### 5. Open access to data and code

Question: Does the paper provide open access to the data and code, with sufficient instructions to faithfully reproduce the main experimental results, as described in supplemental material?

Answer: [Yes]

Justification: The code will be released upon publication.

Guidelines:

- The answer NA means that paper does not include experiments requiring code.
- Please see the NeurIPS code and data submission guidelines (<https://nips.cc/public/guides/CodeSubmissionPolicy>) for more details.
- While we encourage the release of code and data, we understand that this might not be possible, so “No” is an acceptable answer. Papers cannot be rejected simply for not including code, unless this is central to the contribution (e.g., for a new open-source benchmark).
- The instructions should contain the exact command and environment needed to run to reproduce the results. See the NeurIPS code and data submission guidelines (<https://nips.cc/public/guides/CodeSubmissionPolicy>) for more details.
- The authors should provide instructions on data access and preparation, including how to access the raw data, preprocessed data, intermediate data, and generated data, etc.
- The authors should provide scripts to reproduce all experimental results for the new proposed method and baselines. If only a subset of experiments are reproducible, they should state which ones are omitted from the script and why.
- At submission time, to preserve anonymity, the authors should release anonymized versions (if applicable).
- Providing as much information as possible in supplemental material (appended to the paper) is recommended, but including URLs to data and code is permitted.

## 6. Experimental setting/details

Question: Does the paper specify all the training and test details (e.g., data splits, hyperparameters, how they were chosen, type of optimizer, etc.) necessary to understand the results?

Answer: [Yes]

Justification: Details are given in Section 4.1 and in the Appendix.

Guidelines:

- The answer NA means that the paper does not include experiments.
- The experimental setting should be presented in the core of the paper to a level of detail that is necessary to appreciate the results and make sense of them.
- The full details can be provided either with the code, in appendix, or as supplemental material.

## 7. Experiment statistical significance

Question: Does the paper report error bars suitably and correctly defined or other appropriate information about the statistical significance of the experiments?

Answer: [Yes]

Justification: We report standard errors obtained over several replicas in the Appendix.

Guidelines:

- The answer NA means that the paper does not include experiments.
- The authors should answer "Yes" if the results are accompanied by error bars, confidence intervals, or statistical significance tests, at least for the experiments that support the main claims of the paper.
- The factors of variability that the error bars are capturing should be clearly stated (for example, train/test split, initialization, random drawing of some parameter, or overall run with given experimental conditions).
- The method for calculating the error bars should be explained (closed form formula, call to a library function, bootstrap, etc.)
- The assumptions made should be given (e.g., Normally distributed errors).
- It should be clear whether the error bar is the standard deviation or the standard error of the mean.



- It is OK to report 1-sigma error bars, but one should state it. The authors should preferably report a 2-sigma error bar than state that they have a 96% CI, if the hypothesis of Normality of errors is not verified.
- For asymmetric distributions, the authors should be careful not to show in tables or figures symmetric error bars that would yield results that are out of range (e.g. negative error rates).
- If error bars are reported in tables or plots, The authors should explain in the text how they were calculated and reference the corresponding figures or tables in the text.

#### 8. Experiments compute resources

Question: For each experiment, does the paper provide sufficient information on the computer resources (type of compute workers, memory, time of execution) needed to reproduce the experiments?

Answer: [Yes]

Justification: Details are provided in the Appendix.

Guidelines:

- The answer NA means that the paper does not include experiments.
- The paper should indicate the type of compute workers CPU or GPU, internal cluster, or cloud provider, including relevant memory and storage.
- The paper should provide the amount of compute required for each of the individual experimental runs as well as estimate the total compute.
- The paper should disclose whether the full research project required more compute than the experiments reported in the paper (e.g., preliminary or failed experiments that didn't make it into the paper).

#### 9. Code of ethics

Question: Does the research conducted in the paper conform, in every respect, with the NeurIPS Code of Ethics <https://neurips.cc/public/EthicsGuidelines>?

Answer: [Yes]

Justification: The research conducted in the paper conforms with the NeurIPS Code of Ethics.

Guidelines:

- The answer NA means that the authors have not reviewed the NeurIPS Code of Ethics.
- If the authors answer No, they should explain the special circumstances that require a deviation from the Code of Ethics.
- The authors should make sure to preserve anonymity (e.g., if there is a special consideration due to laws or regulations in their jurisdiction).

#### 10. Broader impacts

Question: Does the paper discuss both potential positive societal impacts and negative societal impacts of the work performed?

Answer: [Yes]

Justification: We discuss the broader impacts of our work in Sections 1 and 5.

Guidelines:

- The answer NA means that there is no societal impact of the work performed.
- If the authors answer NA or No, they should explain why their work has no societal impact or why the paper does not address societal impact.
- Examples of negative societal impacts include potential malicious or unintended uses (e.g., disinformation, generating fake profiles, surveillance), fairness considerations (e.g., deployment of technologies that could make decisions that unfairly impact specific groups), privacy considerations, and security considerations.

- The conference expects that many papers will be foundational research and not tied to particular applications, let alone deployments. However, if there is a direct path to any negative applications, the authors should point it out. For example, it is legitimate to point out that an improvement in the quality of generative models could be used to generate deepfakes for disinformation. On the other hand, it is not needed to point out that a generic algorithm for optimizing neural networks could enable people to train models that generate Deepfakes faster.
- The authors should consider possible harms that could arise when the technology is being used as intended and functioning correctly, harms that could arise when the technology is being used as intended but gives incorrect results, and harms following from (intentional or unintentional) misuse of the technology.
- If there are negative societal impacts, the authors could also discuss possible mitigation strategies (e.g., gated release of models, providing defenses in addition to attacks, mechanisms for monitoring misuse, mechanisms to monitor how a system learns from feedback over time, improving the efficiency and accessibility of ML).

## 11. Safeguards

Question: Does the paper describe safeguards that have been put in place for responsible release of data or models that have a high risk for misuse (e.g., pretrained language models, image generators, or scraped datasets)?

Answer: [NA]

Justification: The paper poses no such risks.

Guidelines:

- The answer NA means that the paper poses no such risks.
- Released models that have a high risk for misuse or dual-use should be released with necessary safeguards to allow for controlled use of the model, for example by requiring that users adhere to usage guidelines or restrictions to access the model or implementing safety filters.
- Datasets that have been scraped from the Internet could pose safety risks. The authors should describe how they avoided releasing unsafe images.
- We recognize that providing effective safeguards is challenging, and many papers do not require this, but we encourage authors to take this into account and make a best faith effort.

## 12. Licenses for existing assets

Question: Are the creators or original owners of assets (e.g., code, data, models), used in the paper, properly credited and are the license and terms of use explicitly mentioned and properly respected?

Answer: [Yes]

Justification: Code (Boltz-1, AlphaFold3, ModelAngelo), software (ChimeraX) and data (PDB, EMDb) are properly credited and cited.

Guidelines:

- The answer NA means that the paper does not use existing assets.
- The authors should cite the original paper that produced the code package or dataset.
- The authors should state which version of the asset is used and, if possible, include a URL.
- The name of the license (e.g., CC-BY 4.0) should be included for each asset.
- For scraped data from a particular source (e.g., website), the copyright and terms of service of that source should be provided.
- If assets are released, the license, copyright information, and terms of use in the package should be provided. For popular datasets, [paperswithcode.com/datasets](https://paperswithcode.com/datasets) has curated licenses for some datasets. Their licensing guide can help determine the license of a dataset.
- For existing datasets that are re-packaged, both the original license and the license of the derived asset (if it has changed) should be provided.

- If this information is not available online, the authors are encouraged to reach out to the asset's creators.

### 13. **New assets**

Question: Are new assets introduced in the paper well documented and is the documentation provided alongside the assets?

Answer: [NA]

Justification: The paper does not release new assets.

Guidelines:

- The answer NA means that the paper does not release new assets.
- Researchers should communicate the details of the dataset/code/model as part of their submissions via structured templates. This includes details about training, license, limitations, etc.
- The paper should discuss whether and how consent was obtained from people whose asset is used.
- At submission time, remember to anonymize your assets (if applicable). You can either create an anonymized URL or include an anonymized zip file.

### 14. **Crowdsourcing and research with human subjects**

Question: For crowdsourcing experiments and research with human subjects, does the paper include the full text of instructions given to participants and screenshots, if applicable, as well as details about compensation (if any)?

Answer: [NA]

Justification: The paper does not involve crowdsourcing nor research with human subjects.

Guidelines:

- The answer NA means that the paper does not involve crowdsourcing nor research with human subjects.
- Including this information in the supplemental material is fine, but if the main contribution of the paper involves human subjects, then as much detail as possible should be included in the main paper.
- According to the NeurIPS Code of Ethics, workers involved in data collection, curation, or other labor should be paid at least the minimum wage in the country of the data collector.

### 15. **Institutional review board (IRB) approvals or equivalent for research with human subjects**

Question: Does the paper describe potential risks incurred by study participants, whether such risks were disclosed to the subjects, and whether Institutional Review Board (IRB) approvals (or an equivalent approval/review based on the requirements of your country or institution) were obtained?

Answer: [NA]

Justification: The paper does not involve crowdsourcing nor research with human subjects.

Guidelines:

- The answer NA means that the paper does not involve crowdsourcing nor research with human subjects.
- Depending on the country in which research is conducted, IRB approval (or equivalent) may be required for any human subjects research. If you obtained IRB approval, you should clearly state this in the paper.
- We recognize that the procedures for this may vary significantly between institutions and locations, and we expect authors to adhere to the NeurIPS Code of Ethics and the guidelines for their institution.
- For initial submissions, do not include any information that would break anonymity (if applicable), such as the institution conducting the review.

### 16. **Declaration of LLM usage**

Question: Does the paper describe the usage of LLMs if it is an important, original, or non-standard component of the core methods in this research? Note that if the LLM is used only for writing, editing, or formatting purposes and does not impact the core methodology, scientific rigorousness, or originality of the research, declaration is not required.

Answer: [NA]

Justification: The core method development in this research does not involve LLMs as any important, original, or non-standard components.

Guidelines:

- The answer NA means that the core method development in this research does not involve LLMs as any important, original, or non-standard components.
- Please refer to our LLM policy (<https://neurips.cc/Conferences/2025/LLM>) for what should or should not be described.